These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38185772)

  • 41. Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3).
    Blauvelt A; Papp KA; Griffiths CEM; Puig L; Weisman J; Dutronc Y; Kerr LF; Ilo D; Mallbris L; Augustin M
    Am J Clin Dermatol; 2017 Apr; 18(2):273-280. PubMed ID: 28074446
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ixekizumab: a new anti-IL-17A monoclonal antibody therapy for moderate-to severe plaque psoriasis.
    Blauvelt A
    Expert Opin Biol Ther; 2016; 16(2):255-63. PubMed ID: 26666707
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ixekizumab: A Review of Its Use for the Management of Moderate to Severe Plaque Psoriasis.
    Shelton SK; Bai SR; Jordan JK; Sheehan AH
    Ann Pharmacother; 2019 Mar; 53(3):276-284. PubMed ID: 30187769
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment of moderate-to-severe psoriasis in the UK.
    Johansson EC; Hartz S; Kiri SH; Kumar G; Svedbom A
    J Med Econ; 2018 Aug; 21(8):810-820. PubMed ID: 29873270
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis.
    Reich K; Conrad C; Kristensen LE; Smith SD; Puig L; Rich P; Sapin C; Holzkaemper T; Koppelhus U; Schuster C
    J Dermatolog Treat; 2022 May; 33(3):1652-1660. PubMed ID: 33641593
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis.
    Vu TT; Gooderham M; Papp K
    Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1423-1433. PubMed ID: 27690669
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy.
    Giunta A; Ventura A; Chimenti MS; Bianchi L; Esposito M
    Drug Des Devel Ther; 2017; 11():1643-1651. PubMed ID: 28652702
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Understanding characteristics of patients newly initiating ixekizumab: findings from the Corrona Psoriasis Registry.
    Wu JJ; Harrison RW; Zhu B; Goldblum OM; Malatestinic WN; Burge R; Murage MJ
    J Comp Eff Res; 2021 Feb; 10(2):157-167. PubMed ID: 33355477
    [No Abstract]   [Full Text] [Related]  

  • 49. Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3.
    van de Kerkhof P; Guenther L; Gottlieb AB; Sebastian M; Wu JJ; Foley P; Morita A; Goldblum O; Zhang L; Erickson J; Ball S; Rich P
    J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):477-482. PubMed ID: 27910156
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2).
    Rich P; Gooderham M; Bachelez H; Goncalves J; Day RM; Chen R; Crowley J
    J Am Acad Dermatol; 2016 Jan; 74(1):134-42. PubMed ID: 26549249
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis.
    Egeberg A; Bryld LE; Skov L
    J Am Acad Dermatol; 2019 Jul; 81(1):173-178. PubMed ID: 30914343
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Successful treatment of psoriatic crumbly nails with ustekinumab.
    Galluzzo M; D'Adamio S; Chimenti MS; Teoli M; Bianchi L; Talamonti M
    Dermatol Ther; 2019 May; 32(3):e12914. PubMed ID: 30968520
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Determination of the Nail Psoriasis Severity Index improvement rate standards for nail psoriasis treatment in a phase IV clinical trial of ustekinumab: the MARCOPOLO study.
    Youn SW; Kim BR; Cho S; Seo SJ; Lee ES; Roh JY; Choi GS; Lee MG;
    J Eur Acad Dermatol Venereol; 2017 Jun; 31(6):e298-e299. PubMed ID: 27976465
    [No Abstract]   [Full Text] [Related]  

  • 54. Real life long-term efficacy and safety of ixekizumab in moderate-to-severe psoriasis: A 192 weeks multicentric retrospective study-IL PSO (Italian landscape psoriasis).
    Malagoli P; Dapavo P; Pavia G; Amoruso F; Argenziano G; Bardazzi F; Burlando M; Carrera CG; Damiani G; Dini V; Girolomoni G; Guarneri C; Loconsole F; Narcisi A; Sampogna F; Travaglini M; Costanzo A
    Dermatol Ther; 2022 Aug; 35(8):e15608. PubMed ID: 35638250
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3).
    Menter A; Warren RB; Langley RG; Merola JF; Kerr LN; Dennehy EB; Shrom D; Amato D; Okubo Y; Reich K
    J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1686-1692. PubMed ID: 28322474
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Severe 20-nail psoriasis successfully treated by low dose methotrexate.
    Lee JY
    Dermatol Online J; 2009 Nov; 15(11):8. PubMed ID: 19951644
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Use of secukinumab in a pediatric patient leads to significant improvement in nail psoriasis and psoriatic arthritis.
    Wells LE; Evans T; Hilton R; Wine Lee L; Ruth N
    Pediatr Dermatol; 2019 May; 36(3):384-385. PubMed ID: 30811618
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial.
    Paller AS; Seyger MMB; Magariños GA; Pinter A; Cather JC; Rodriguez-Capriles C; Zhu D; Somani N; Garrelts A; Papp KA;
    JAMA Dermatol; 2022 May; 158(5):533-541. PubMed ID: 35416908
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Management of nail psoriasis.
    Thomas L; Azad J; Takwale A
    Clin Exp Dermatol; 2021 Jan; 46(1):3-8. PubMed ID: 32741010
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anti-TNF agents and nail psoriasis: a single-center, retrospective, comparative study.
    Kyriakou A; Patsatsi A; Sotiriadis D
    J Dermatolog Treat; 2013 Jun; 24(3):162-8. PubMed ID: 22136334
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.